Novel targeted therapies for metastatic breast cancer.
Breast cancer (BC)
novel agents
targeted therapy
Journal
Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
entrez:
15
8
2020
pubmed:
15
8
2020
medline:
15
8
2020
Statut:
ppublish
Résumé
Metastatic breast cancer (mBC) continues to be a leading cause of cancer-related death in women. Even though mortality rates have improved over recent years, the 5-year survival rate of advanced BC is still at only 27%. As researchers and clinicians attempt to tackle this challenge, there has been extensive research and many trials studying treatment options for BC patients with metastatic disease, with numerous new therapies being discovered as a result. We review the most pertinent novel agents to enter the scope of BC treatment, including CDK4/6 inhibitors, PI3K inhibitors, mTOR inhibitors, immunotherapy, PARP inhibitors, and more.
Identifiants
pubmed: 32793751
doi: 10.21037/atm.2020.03.43
pii: atm-08-14-907
pmc: PMC7396776
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
907Informations de copyright
2020 Annals of Translational Medicine. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm.2020.03.43). The series “Cancer Metastasis: Molecular signaling and therapeutic options” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.
Références
Wiley Interdiscip Rev Syst Biol Med. 2017 Jul;9(4):
pubmed: 28186392
J Pathol Clin Res. 2015 Jul 20;1(4):225-38
pubmed: 27499907
PLoS One. 2015 Oct 15;10(10):e0140479
pubmed: 26469692
N Engl J Med. 2019 Feb 21;380(8):741-751
pubmed: 30786188
JAMA Oncol. 2019 Sep 29;:
pubmed: 31563959
Bioconjug Chem. 2019 Mar 20;30(3):907-919
pubmed: 30739442
Clin Med Insights Oncol. 2016 Apr 05;10(Suppl 1):31-9
pubmed: 27081325
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
J Clin Oncol. 2019 Oct 10;37(29):2601-2609
pubmed: 31442103
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
Mol Cancer. 2011 Jun 13;10:72
pubmed: 21668989
Future Oncol. 2012 Jun;8(6):651-7
pubmed: 22764762
Cancer Discov. 2016 Apr;6(4):353-67
pubmed: 26658964
Am J Cancer Res. 2019 Oct 01;9(10):2103-2119
pubmed: 31720077
N Engl J Med. 2016 Nov 3;375(18):1738-1748
pubmed: 27717303
Breast Cancer Res Treat. 2011 Jul;128(2):347-56
pubmed: 20730488
J Clin Oncol. 2017 Nov 10;35(32):3638-3646
pubmed: 28968163
Breast Cancer Res. 2009;11(5):R77
pubmed: 19874578
Nat Commun. 2016 May 10;7:11479
pubmed: 27161491
Nat Med. 2019 Jun;25(6):920-928
pubmed: 31086347
J Clin Oncol. 2016 Jul 20;34(21):2460-7
pubmed: 27138582
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
N Engl J Med. 2019 Jul 25;381(4):307-316
pubmed: 31166679
Lancet. 2015 Oct 3;386(10001):1341-1352
pubmed: 26211827
Lancet Oncol. 2014 Jun;15(7):689-99
pubmed: 24793816
Ann Oncol. 2016 May;27(5):812-8
pubmed: 27052658
Lancet Oncol. 2015 Jan;16(1):25-35
pubmed: 25524798
Front Biosci. 2006 Jan 01;11:1164-88
pubmed: 16146805
Lancet Oncol. 2017 Dec;18(12):1688-1700
pubmed: 29146401
Clin Cancer Res. 2017 Jan 1;23(1):26-34
pubmed: 27126994
Clin Cancer Res. 2013 Oct 1;19(19):5505-12
pubmed: 23965901
Ann Oncol. 2009 Dec;20(12):1913-27
pubmed: 19901010
J Clin Oncol. 2012 Jan 20;30(3):282-90
pubmed: 22162589
Lancet Oncol. 2017 Jul;18(7):904-916
pubmed: 28576675
Oncotarget. 2016 Jul 19;7(29):46482-46491
pubmed: 27374089
Clin Cancer Res. 2020 Jan 15;26(2):354-363
pubmed: 31619444
Ann Oncol. 2019 May 1;30(5):774-780
pubmed: 30860570
Cancer Chemother Pharmacol. 2013 Apr;71(4):829-42
pubmed: 23377372
Invest New Drugs. 2014 Aug;32(4):670-81
pubmed: 24652201
N Engl J Med. 2016 Nov 17;375(20):1925-1936
pubmed: 27959613
Nat Rev Cancer. 2006 Sep;6(9):729-34
pubmed: 16915295
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
N Engl J Med. 2015 Feb 19;372(8):724-34
pubmed: 25693012
Br Med Bull. 2009;89:23-40
pubmed: 19208614
N Engl J Med. 2015 Jul 16;373(3):209-19
pubmed: 26030518
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Eur J Cancer. 2018 Nov;103:147-154
pubmed: 30241001
N Engl J Med. 2020 Feb 13;382(7):597-609
pubmed: 31825569
J Clin Oncol. 2013 Jun 10;31(17):2128-35
pubmed: 23650416
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
J Clin Oncol. 2017 Jul 1;35(19):2141-2148
pubmed: 28291390
Ann Oncol. 2014 Nov;25(11):2244-2251
pubmed: 25193991
Oncologist. 2008 Oct;13(10):1114-9
pubmed: 18849320
Lancet Oncol. 2014 May;15(6):580-91
pubmed: 24742739
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
J Clin Oncol. 2017 Sep 1;35(25):2875-2884
pubmed: 28580882
Lancet Oncol. 2017 Oct;18(10):1360-1372
pubmed: 28800861